BMC Pharmacology & Toxicology · 7 authors, 6 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
A 15-day acute dermal toxicity study in Sprague-Dawley rats found that AT-533 at doses of 5 and 50 mg/kg caused no adverse effects, while 250 and 500 mg/kg doses were toxic and caused mortality, yielding an LD50 of 228.382 mg/kg. AT-533 gel at 5 g/kg produced no mortality or toxic effects, with an LD50 exceeding 5 g/kg.
This 15-day acute dermal toxicity study evaluated AT-533, a heat shock protein 90 inhibitor, and its gel formulation in male and female Sprague-Dawley rats. AT-533 was administered percutaneously at 5, 50, 250, and 500 mg/kg, and AT-533 gel at 5 g/kg. No abnormal changes were observed in rats treated with AT-533 at 5 or 50 mg/kg or with AT-533 gel. A decreased lymphocyte level at 50 mg/kg was within normal reference ranges and not considered toxicologically relevant. Only 1 to 2 rats survived at 250 and 500 mg/kg, limiting the reliability of biochemical and organ coefficient data at those doses. AT-533 gel at 5 g/kg caused no mortality, no hematological abnormalities, and normal histopathological findings across major organs. The LD50 of AT-533 gel exceeded 5 g/kg.
